A novel BET family bromodomain inhibitor NHWD‐870 represents a promising therapeutic agent for a broad spectrum of cancers
Yin M, Wang N, Yan Q. A novel BET family bromodomain inhibitor NHWD‐870 represents a promising therapeutic agent for a broad spectrum of cancers. The FASEB Journal 2017, 31 DOI: 10.1096/fasebj.31.1_supplement.979.3.Peer-Reviewed Original ResearchTumor cellsMouse models of small cell lung cancerModels of small cell lung cancerInhibition of tumor angiogenesisSmall cell lung cancerSpectrum of activity in vitroTriple negative breast cancerSingle agent activitySolid tumor indicationsCell lung cancerInhibition of tumor cell growthNegative breast cancerTumor suppression efficacyNHWD-870Xenograft mouse modelTumor cell growthDiverse mechanisms of actionBET family bromodomain inhibitorsMEK1/2 signalingCancer cell linesOvarian cancerMechanism of actionSolid tumorsTumor indicationsTumor angiogenesis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply